



09-10-03

RCE/1600  
Box 25

PTO/SB/30 (5/2000)

Approved for use through xx/xx/xxxx. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST  
FOR  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000,  
provides for continued examination of an utility or plant application  
filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/145,916
Filing Date	Sept. 2, 1998
First Named Inventor	Michael Simons
Group Art Unit	1636
Examiner Name	David Guzo
Attorney Docket Number	BIS-039/CE

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

**NOTE:** 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.1. **Submission required under 37 C.F.R. § 1.114**

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☒ Other Sequence Listing, 37 C.F.R. 1.821-1.825

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.114(a) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.114(b) is required.)
- b. ☐ Other \_\_\_\_\_

3. **Fees** The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a. ☐ The Director is hereby authorized to charge the following fees, or credit any overpayment to the Deposit Account No. \_\_\_\_\_
- i. ☐ RCE fee required under 37 C.F.R. § 1.17(e)
- ii. ☐ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Check in the amount of \$ 375.00 enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

DATE: \_\_\_\_\_  
**DISK TO STIC**  
PATENT & TRADEMARK OFFICE  
SEP 09 2003**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	David Prashker	Registration No. (Attorney/Agent)	No. 29,693
Signature	<i>David Prashker</i>	Date	Sept. 9, 2003

**CERTIFICATE OF MAILING OR TRANSMISSION**I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:

Name (Print/Type)	_____	Date	_____
Signature	_____		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patents, Box RCE, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Simons *et al.*  
Serial No. : 09/145,916  
Filed : September 2, 1998  
For : "STIMULATION OF ANGIOGENESIS VIA  
ENHANCED ENDOTHELIAL EXPRESSION  
OF SYNDECAN-4 CORE PROTEINS"  
Examiner : David Guzo  
Group Art Unit : 1636  
Attorney's Docket No. : BIS-039

\*\*\*\*\*

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Mail Stop: RCE, Alexandria, Virginia 22313-1450 on: \_\_\_\_\_.

Attorney for applicants: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_


\*\*\*\*\*

AMENDMENT OF SPECIFICATION AND REQUEST FOR ENTRY OF  
A THIRD PAPER FORM COPY OF THE SEQUENCE LISTING  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents  
P.O. Box 1540  
Mail Stop: RCE  
Alexandria, Virginia 22313-1450

Dear Sir:

RECEIVED  
SEP 15 2003  
TECH CENTER



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Simons *et al.*  
Serial No. : 09/145,916  
Filed : September 2, 1998  
For : "STIMULATION OF ANGIOGENESIS VIA  
ENHANCED ENDOTHELIAL CELL EXPRESSION  
OF SYNDECAN-4 CORE PROTEINS"

Examiner : David Guzo  
Group Art Unit : 1636  
Attorney's Docket No. : BIS-039

\*\*\*\*\*

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed to  
Commission for Patents, P.O. Box 1450, Mail Stop: RCE, Alexandria,  
Virginia 22313-1450 on: \_\_\_\_\_

Attorney for applicants: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

\*\*\*\*\*

AMENDMENT AND RESPONSE SUBMITTED PURSUANT  
TO 37 C.F.R.1.114 IN SUPPORT OF THE  
REQUEST FOR CONTINUING EXAMINATION

Commissioner for Patents  
P.O. Box 1450  
Mail Stop: RCE  
Alexandria, Virginia 22313-1450

Sir:

As part of the documents supporting the instant Request For Continuing Examination filed herewith in the U.S. Patent Office, applicants respectfully present their substantive Response in full to the most recently received (final) Official Action mailed April 11, 2003 for the above-identified application.

As a matter of substantive legal right, therefore, applicants hereby amend the Specification at page 29, lines 19-20; amend claims 1-3 and 12-13 respectively; and retain pending claims 4-8 and 11 respectively in unaltered form. The amendment to the Specification text, in clean copy and marked-up versions, is presented by the supporting documentary enclosures submitted herewith. Also, in view of the revised amendment practice (which became mandatory on July 30<sup>th</sup>, 2003), applicants now present the language for each of presently pending amended claims 1-3 and 12-13 respectively and for each of retained unaltered claims 4-8 and 11 respectively. The text of the currently pending claims begins on the immediately following page.